MedTrace Logo

Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment

NCT05387330 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2022-05-24

No results posted yet for this study

Summary

This study aims to monitor the levels of soluble L-selectin (sCD62L) and secreted protein acidic rich in cysteine (SPARC) in chronic phase chronic myeloid leukemia (CP-CML) patients at baseline and after three and six months of imatinib therapy and evaluated the effect of imatinib on their levels and correlated their levels to clinical and laboratory parameters.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DIAGNOSTIC_TEST

ELISA kit

Sandwich ELISA kit for the accurate quantitative detection of sCD62L and SPARC in human plasma and serum samples.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Mahmoud M Elkholy, Bachelor · Clinical Pharmacy Department, Faculty of Pharmacy, Al Salam University in Egypt

  • Sahar M El-Haggar, Ph D · Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University

  • Maryan W Fahmi, Ph D · Medical oncology unit, Internal medicine Department, Faculty of medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2021-07-25
Completion
2021-12-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05387330 on ClinicalTrials.gov